Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 90/100

Failure Rate

33.3%

2 terminated/withdrawn out of 6 trials

Success Rate

50.0%

-36.5% vs industry average

Late-Stage Pipeline

17%

1 trials in Phase 3/4

Results Transparency

0 of 2 completed trials have results

Key Signals

Enrollment Performance

Analytics

Phase 2

4(66.7%)

Phase 1

1(16.7%)

Phase 3

1(16.7%)

6Total

Phase 2(4)

Phase 1(1)

Phase 3(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (6)

Showing 6 of 6 trials

NCT02727881Phase 3Unknown

Efficacy and Safety Study of Squalamine Ophthalmic Solution in Subjects With Neovascular AMD

Role: lead

NCT02511613Phase 2Withdrawn

Effect of Squalamine Lactate Ophthalmic Solution, 0.2% in Subjects With Neovascular Age-Related Macular Degeneration

Role: lead

NCT02349516Phase 2Withdrawn

Squalamine Lactate Eye Drops in Combination With Ranibizumab in Patients With Diabetic Macular Edema (DME)

Role: collaborator

NCT02614937Phase 1Completed

Study of Squalamine Lactate for the Treatment of Macular Edema Related to Retinal Vein Occlusion

Role: lead

NCT01678963Phase 2Completed

Efficacy and Safety of Squalamine Lactate Eye Drops in Subjects With Neovascular (Wet) Age-related Macular Degeneration (AMD)

Role: lead

NCT01206335Phase 2Unknown

Open Label Study With OHR/AVR118 in Advanced Cancer Patients With Anorexia-Cachexia

Role: lead

All 6 trials loaded